Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial

Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease and hepatocellular carcinoma. Treatment with first generation protease inhibitors (PI)  + peg-interferon (pegIFN) and ribavirin (RBV...

Source: BMC Infectious Diseases - April 3, 2020 Category: Infectious Diseases Authors: Liat Deutsch, Inbal Houri, Ziv Ben-Ari, Amir Shlomai, Ella Veitsman, Oranit Cohen-Ezra, Assaf Issachar, Orna Mor, Yael Gozlan, Rafael Bruck, Yoram Menachem, Shira Zelber-Sagi, Helena Katchman and Oren Shibolet Tags: Research article Source Type: research